18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Neuroendocrine Tumors Clinical Trial

Official title:

A Phase I/IIA Study of 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02348749
• Other study ID #: 14-138
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: January 2015
• Est. completion date: January 2025

Study information

• Verified date: April 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see how a new tracer named 18F-MFBG (Meta Fluorobenzyl Guanidine) behaves in the body after injection, how it spreads to all the organs and how it is removed from the body. We will also study how long 18F-MFBG lasts in the blood after administered. In addition we want to study if 18F-MFBG can show Neuroendocrine tumors on a PET-CT or PET MR scan.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

Phase I:

• Eligible patients include patients with histologically proven Neuroendocrine tumors (paraganglioma, PHEO, or well differentiated NET of the lung or GI system) or NB. Patients who have NB, the diagnosis must be in accordance with the International Criteria, i.e., either histopathology or bone marrow involvement. Patients must be =5 years of age and able to undergo PET scan without sedation
• All patients must have MIBG-avid disease and evaluable disease on MIBG scan at the time of enrollment onto the protocol.
• Performance status of =60 on Karnofsky scale for patients >16 years of age and >60 on Lansky scale for patients <16 years of age.
• Cardiac, pulmonary, gastrointestinal and neurologic toxicity should all be =grade 2.

Expansion Cohort:

• Patients with diagnosis of NB (in accordance with the International Criteria, i.e., either histopathology or bone marrow involvement)
• Patients must be able to undergo PET scan without sedation
• Patients must have prior MIBG-avid disease and evaluable disease on MIBG scan at the time of enrollment onto the protocol.
• If MIBG scan is available within 4 weeks of MFBG, with no intervening treatment, MIBG scan will not be repeated.
• If prior MIBG scan is available >4 weeks of MFBG, MIBG scan will be done within a week (prior or after) of MFBG.
• Performance status of =60 on Karnofsky scale for patients >16 years of age and >60 on Lansky scale for patients =16 years of age.
• Cardiac, pulmonary, gastrointestinal and neurologic toxicity should all be =grade 2.
• Patients with positive lesion detection by 18F-MFBG may be eligible for repeat imaging scan, at the discretion of PI or study investigator(s).

Exclusion Criteria:

• Major organ toxicity including cardiac, pulmonary, gastrointestinal and neurologic toxicity more than grade 2.
• Active serious infections not controlled by antibiotics.
• Inability or unwillingness to undergo PET scanning
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Women who are pregnant or breastfeeding.
• Patient has an active malignancy of metastatic potential other than the known NE tumor for the past 3 years.
• Patients should not have received chemotherapy or radiation therapy (localized radiation therapy is allowed to non-evaluable sites) between prior 123I-MIBG scan and 18F-MFBG administration.
• Patients requiring anesthesia, who are not already undergoing anesthesia for standard-of-care procedures.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Radiation:
• 18F-MFBG (meta-fluoro benzylguanidine)
About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.

Device:
• Positron emission tomography (PET) imaging
Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.

Other:
• Blood draws
Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	dosimetry of 18F MFBG	in two cohorts of patients: (a) those with NB and (b) those with non-NB NE. Data will be derived from blood draws and PET/CT scans at multiple time points after injection of 18F-MFBG IV.	1 year
Primary	radioactivity	Multiple samples will be counted and time activity curve generated for evaluation of serum clearance. Blood samples will be centrifuged and the plasma pipetted, weighed and counted to determine the plasma time activity concentration curves (% injected dose/liter), as well as for metabolite analysis of the 18F-MFBG compound by HPLC and/or TCA methodology.	1 year
Secondary	18 F-MFBG imaging PET/CT to target known sites of disease	Lesion detection will be evaluated based on per patient and per lesion basis. The segmental distribution method described for 123 I -MIBG imaging (modified curie scoring system will be used- appendix C). If, for each individual patient, there is a concordance of =70% of segments or lesion detection between MIBG and 18 F-MFBG , the latter will be considered as effectively targeting lesions. For discordant lesions, if MFBG imaging shows 2 or more lesions that are positive on other concurrent or follow up conventional imaging, it will be considered optimal targeting.	1 year

External Links

•   Memorial Sloan Kettering Cancer Center